Mereo BioPharma Group plc

What they do

Mereo develops therapeutics for rare diseases, focusing on late-stage clinical candidates. Its lead program, setrusumab, targets osteogenesis imperfecta, and alvelestat targets severe alpha-1 antitrypsin deficiency-associated lung disease. The company also has an early-stage program, vantictumab, partnered with shibio for autosomal dominant osteopetrosis Type 2, retaining European commercial rights.

Revenue drivers

• Setrusumab — Late-stage candidate for osteogenesis imperfecta; partnered with Ultragenyx; Mereo retains European and U.K. commercial rights. No approved product or revenue yet.
• Alvelestat — Late-stage candidate for AATD-LD; option and license agreement with Sentynl Therapeutics could yield $40M upfront/R&D, up to $435M milestones, and double-digit royalties on U.S. sales. No revenue yet.
• Vantictumab — Early-stage rare disease program for ADO2; development funded and led by partner shibio; Mereo retains European commercial rights. No revenue contribution.
• Partnership and licensing income — Revenue has been minimal ($0.5M in 2025 and H1 2026), primarily from collaboration agreements rather than product sales.

Recent performance

For Q2 2026, the company reported revenue of $0.5 million, up from $0.5M in Q2 2025 (not provided in excerpt). Cash and cash equivalents were $30.1 million at June 30, 2026, with total assets of $34.7M and shareholder equity of $28.7M. Net loss for 2025 was $41.9 million, similar to 2024's $43.3 million net loss. Operating cash flow was negative $31.0 million in 2025.

Strategy

Mereo aims to rapidly develop and commercialize its late-stage rare disease candidates, leveraging partnerships for funding and regional rights. It seeks to be a preferred partner for pharma companies, as shown by agreements with Ultragenyx, Novartis, AstraZeneca, and Sentynl. The company focuses on regulatory pathways for rare diseases and may commercialize select products in Europe and the U.K. while out-licensing other regions.

Risks

• No approved products or product revenue — The company has never generated revenue from product sales and expects significant operating losses as it invests in R&D.
• Phase 3 setrusumab missed primary endpoints — The Orbit and Cosmic studies did not achieve statistical significance on fracture rate reduction, which may delay or prevent regulatory approval.
• Regulatory uncertainty for setrusumab — The FDA is open to alternative analyses, but further clinical data may be required to support a BLA, with no guaranteed path to approval.
• Dependence on partnership execution — The alvelestat program depends on Sentynl exercising its option; if not, the upfront and milestone payments may not materialize, and cash runway could be short.

Outlook

Management expects cash of $30.1 million to fund operations into late-2027, excluding potential $40 million payments from Sentynl on option exercise. They plan to initiate the Phase 3 trial for alvelestat in early 2027 if the option is exercised. For setrusumab, regulatory discussions with FDA and MHRA are ongoing, with an update expected by year-end 2026.